Matthew Kulke

Matthew Helmut Kulke
Alma materPrinceton University
UCSF School of Medicine
Harvard Medical School
Occupation(s)Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Boston University School of Medicine.
Years active1992-Present[1]

Matthew Kulke is an American cancer researcher. He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine.[2][3] His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition.[4][5] His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor,[6] for the treatment of patients with carcinoid syndrome.[7] He has also contributed to early and late stage clinical trials of temozolomide, sunitinib,[8] everolimus, and peptide receptor radiotherapy for neuroendocrine tumors.[9][10]

  1. ^ "Dr. Matthew Kulke, MD". Health Grades. Retrieved 2020-11-19.
  2. ^ "Matthew Helmut Kulke, MD". Boston University. Retrieved 2020-11-13.
  3. ^ "Matthew Kulke, MD, Joins BUMC". Boston University School of Medicine. 2017-11-21. Retrieved 2020-11-20.
  4. ^ Strosberg, Jonathan; El-Haddad, Ghassan; Wolin, Edward; Hendifar, Andrew; Yao, James; Chasen, Beth; Mittra, Erik; Kunz, Pamela L.; Kulke, Matthew H.; Jacene, Heather; Bushnell, David; o'Dorisio, Thomas M.; Baum, Richard P.; Kulkarni, Harshad R.; Caplin, Martyn; Lebtahi, Rachida; Hobday, Timothy; Delpassand, Ebrahim; Van Cutsem, Eric; Benson, Al; Srirajaskanthan, Rajaventhan; Pavel, Marianne; Mora, Jaime; Berlin, Jordan; Grande, Enrique; Reed, Nicholas; Seregni, Ettore; Öberg, Kjell; Lopera Sierra, Maribel; et al. (2019-01-12). "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors". New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. PMC 5895095. PMID 28076709.
  5. ^ "MATTHEW H. KULKE, MD". NANETS. Retrieved 2020-11-19.
  6. ^ Pavel, Marianne; Gross, David J.; Benavent, Marta; Perros, Petros; Srirajaskanthan, Raj; Warner, Richard R P.; Kulke, Matthew H.; Anthony, Lowell B.; Kunz, Pamela L.; Hörsch, Dieter; Weickert, Martin O.; Lapuerta, Pablo; Jiang, Wenjun; Kassler-Taub, Kenneth; Wason, Suman; Fleming, Rosanna; Fleming, Douglas; Garcia-Carbonero, Rocio (2018). "Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial". Endocrine-Related Cancer. 25 (3): 309–322. doi:10.1530/ERC-17-0455. PMC 5811631. PMID 29330194. Retrieved 2020-11-20.
  7. ^ Kulke, Matthew H.; Hörsch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Öberg, Kjell; Welin, Staffan; Warner, Richard R.P.; Lombard-Bohas, Catherine; Kunz, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; Pavel, Marianne (2017-01-01). "Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome". Journal of Clinical Oncology. 35 (1): 14–23. doi:10.1200/JCO.2016.69.2780. PMID 27918724. Retrieved 2020-11-20.
  8. ^ Kulke, Matthew H.; Lenz, Heinz-Josef; Meropol, Neal J.; Posey, James; Ryan, David P.; Picus, Joel; Bergsland, Emily; Stuart, Keith; Tye, Lesley; Huang, Xin; Li, Jim Z.; Baum, Charles M.; Fuchs, Charles S. (2008). "Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors". Journal of Clinical Oncology. 26 (20): 3403–3410. doi:10.1200/JCO.2007.15.9020. PMID 18612155.
  9. ^ Abbott, Amanda; Sakellis, Christopher G.; Andersen, Eric; Kuzuhara, Yuji; Gilbert, Lauren; Boyle, Kelly; Kulke, Matthew H.; Chan, Jennifer A.; Jacene, Heather A.; Van Den Abbeele, Annick D. (2018-08-03). "Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division". Journal of Nuclear Medicine Technology. 46 (3): 237–244. doi:10.2967/jnmt.118.209148. PMID 30076245. S2CID 51909664. Retrieved 2020-11-20.
  10. ^ "Matthew H Kulke, MD". Boston Medical University. Retrieved 2020-11-13.